PUBLISHER: KBV Research | PRODUCT CODE: 1184477
PUBLISHER: KBV Research | PRODUCT CODE: 1184477
The Asia Pacific Cell Viability Assays Market would witness market growth of 10.7% CAGR during the forecast period (2022-2028).
Identifying the most suitable health assay method that suits the user's requirement requires a proper understanding of the limitations of the assay chemistries, what each assay is measuring as a marker and how the measurement correlates with the cell viability.
Users also choose multiplex-compatible assays to gain more data with a statistical advantage. Cell viability assays indicate metabolically active (living) cells using different markers. Some examples of marker that are generally utilized include measuring ATP levels, detecting enzymatic/protease activities unique to living cells, and measuring the ability to reduce a substrate.
Real-time cell viability assays are utilized to measure the live viability of cells. An engineered prosubstrate and a luciferase are included directly in the culture medium for this assay. The prosubstrate can enter the cell by piercing the cell membrane. However, the prosubstrate can be reduced to the substrate for luciferase only by those viable cells with an active metabolism.
The government of India launched the Free Essential Diagnostics Initiatives under the National health mission to highlight the high out-of-pocket expenditure on diagnostics and enhance the quality of healthcare service quality. The government has launched "Free Diagnostics Services" initiative with the aim to ensure the access and availability of diagnostic tests at public health facilities to reduce out-of-pocket spending by patients on diagnostics.
The China market dominated the Asia Pacific Cell Viability Assays Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $194.9 million by 2028. The Japan market is experiencing a CAGR of 10% during (2022 - 2028). Additionally, The India market would display a CAGR of 11.4% during (2022 - 2028).
Based on Product, the market is segmented into Consumables (Reagents & Assay Kits and Microplates) and Instruments (Spectrophotometer, Microscopy, Cell Imaging & Analysis System, Flow Cytometry, and Others). Based on Reagents & Assay Kits, the market is segmented into Luminometric Assays, Dye Exclusion Assays, Colorimetric Assays, and Fluorometric Assays. Based on End User, the market is segmented into Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes, and Diagnostic Labs. Based on Application, the market is segmented into Stem Cell Research, Drug Discovery & Development, and Diagnostics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company, PerkinElmer Inc., Promega Corporation, Biotium, Creative Bioarray, and Abcam Plc.
Market Segments covered in the Report:
By Product
By End User
By Application
By Country
Companies Profiled
Unique Offerings from KBV Research
List of Figures